Elevai Labs . Common Stock Stock News

NEWPORT BEACH, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Annual Report

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and production in developing countries, and increa...

The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations su

PMGC Holdings Announces Share Repurchases from Existing Shareholders NEWPORT BEACH, Calif., March 26, 2025 -- InvestorsHub NewsWire -- PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our") today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. Details of these transactions are available in the Company's Form 8-K filings on www.sec.gov. The Company will consider rep...

New York, New York, March 24, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based i

NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a

NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from

Northstrive Biosciences Inc. has scheduled a pre-IND meeting with the U.S. Food and Drug Administration for April 23, 2025. EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. NEWPORT BEACH, CA -- March 10, 2025 -- InvestorsHub NewsWire -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (...

NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding company, is proud to announc

NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding company, today announced an upda

Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fir

New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in

NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced i

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium